Search by Drug Name or NDC

NDC 50228-0121-90 Clopidogrel bisulfate 300 mg/1 Details

Clopidogrel bisulfate 300 mg/1

Clopidogrel bisulfate is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ScieGen Pharmaceuticals Inc. The primary component is CLOPIDOGREL BISULFATE.

MedlinePlus Drug Summary

Clopidogrel is used alone or with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a stroke, heart attack, or severe chest pain. This includes people who have percutaneous coronary intervention (PCI; angioplasty; a type of heart surgery) that may involve inserting coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) or who have coronary artery bypass grafting (CABG; a type of heart surgery). Clopidogrel is also used to prevent serious or life-threatening problems with the heart and blood vessels in people who have peripheral arterial disease (poor circulation in the blood vessels that supply blood to the legs). Clopidogrel is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke.

Related Packages: 50228-0121-90
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Clopidogrel

Product Information

NDC	50228-0121
Product ID	50228-121_0789c766-42ac-6467-e063-6294a90a2c6a
Associated GPIs
GCN Sequence Number	n/a
GCN Sequence Number Description	n/a
HIC3	n/a
HIC3 Description	n/a
GCN	n/a
HICL Sequence Number	n/a
HICL Sequence Number Description	n/a
Brand/Generic	n/a
Proprietary Name	Clopidogrel bisulfate
Proprietary Name Suffix	n/a
Non-Proprietary Name	Clopidogrel bisulfate
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	TABLET, FILM COATED
Route	ORAL
Active Ingredient Strength	300
Active Ingredient Units	mg/1
Substance Name	CLOPIDOGREL BISULFATE
Labeler Name	ScieGen Pharmaceuticals Inc
Pharmaceutical Class	Cytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA]
DEA Schedule	n/a
Marketing Category	ANDA
Application Number	ANDA204165
Listing Certified Through	2024-12-31

Package

NDC 50228-0121-90 (50228012190)

Pricing Information	N/A
NDC Package Code	50228-121-90
Billing NDC	50228012190
Package	90 TABLET, FILM COATED in 1 BOTTLE (50228-121-90)
Marketing Start Date	2015-09-15
NDC Exclude Flag	N